Literature DB >> 9663449

The octadecaneuropeptide ODN induces anxiety in rodents: possible involvement of a shorter biologically active fragment.

J G De Mateos-Verchere1, J Leprince, M C Tonon, H Vaudry, J Costentin.   

Abstract

The octadecaneuropeptide ODN has been originally characterized as an endogenous ligand of central-type benzodiazepine receptors, on its ability to displace the anxiogenic compound beta-[3H]carboline-3-carboxylate methyl ester from its binding sites. The aim of the present study was to investigate the anxiogenic effects of intracerebroventricular administration of ODN in mice and rats. At doses ranging from 10 to 100 ng, ODN increased in mice the latency to explore a white compartment when the animals were placed in a black one. ODN also reduced the first stay duration in the white compartment. These effects were antagonized by diazepam (0.075 mg/kg, s.c.) as well as flumazenil (1 mg/kg, s.c.), indicating that ODN acts as an inverse agonist on central-type benzodiazepine receptors. In rats, ODN reduced the latency to enter a black compartment when the animals were placed in the white one. In the plus-maze elevated test, ODN reduced, in both mice and rats, the number of entries and the time spent in the open arm. In mice, ODN (100 ng) increased the thigmotaxis index, i.e. the distance traveled in the peripheral zone of the open field. Time-course studies revealed that a significant effect of ODN (100 ng) in the black/white compartment test was only observed 40 min after the injection and lasted between 3 and 6 h. The effect of a 1000-ng dose of ODN appeared more tardily than that of a 10-ng dose. In addition, a 1000-ng dose of ODN occluded the early effect of a 100-ng dose on the white compartment first stay duration. The COOH-terminal octapeptide of ODN was more rapidly effective than ODN in the black/white compartment test, suggesting that the anxiogenic effect of the peptide requires the formation of biologically active proteolytic fragment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663449     DOI: 10.1016/s0196-9781(98)00037-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

1.  Modulation of ethanol withdrawal-induced anxiety-like behavior during later withdrawals by treatment of early withdrawals with benzodiazepine/gamma-aminobutyric acid ligands.

Authors:  Darin J Knapp; David H Overstreet; George R Breese
Journal:  Alcohol Clin Exp Res       Date:  2005-04       Impact factor: 3.455

Review 2.  Astrocytes: GABAceptive and GABAergic Cells in the Brain.

Authors:  Jianhui Liu; Xuanran Feng; Yi Wang; Xiaohuan Xia; Jialin C Zheng
Journal:  Front Cell Neurosci       Date:  2022-06-10       Impact factor: 6.147

3.  Behavioral effects of flumazenil in the social conflict test in mice.

Authors:  L Uhlírová; M Sustková-Fiserová; M Krsiak
Journal:  Psychopharmacology (Berl)       Date:  2003-09-05       Impact factor: 4.530

4.  Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina.

Authors:  Minhua Wang; Xu Wang; Lian Zhao; Wenxin Ma; Ignacio R Rodriguez; Robert N Fariss; Wai T Wong
Journal:  J Neurosci       Date:  2014-03-05       Impact factor: 6.167

5.  Endogenous positive allosteric modulation of GABA(A) receptors by diazepam binding inhibitor.

Authors:  Catherine A Christian; Anne G Herbert; Rebecca L Holt; Kathy Peng; Kyla D Sherwood; Susanne Pangratz-Fuehrer; Uwe Rudolph; John R Huguenard
Journal:  Neuron       Date:  2013-05-30       Impact factor: 17.173

6.  Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI).

Authors:  Adrien Joseph; Stéphanie Moriceau; Valentina Sica; Gerasimos Anagnostopoulos; Jonathan Pol; Isabelle Martins; Antoine Lafarge; Maria Chiara Maiuri; Marion Leboyer; Josephine Loftus; Frank Bellivier; Raoul Belzeaux; Fabrice Berna; Bruno Etain; Delphine Capdevielle; Philippe Courtet; Caroline Dubertret; Julien Dubreucq; D' Amato Thierry; Guillaume Fond; Sebastien Gard; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Emilie Olié; Christine Passerieux; Mircea Polosan; Paul Roux; Ludovic Samalin; Franck Schürhoff; Raymond Schwan; Christophe Magnan; Franck Oury; José M Bravo-San Pedro; Guido Kroemer
Journal:  Cell Death Dis       Date:  2020-07-06       Impact factor: 8.469

7.  The octadecaneuropeptide ODN protects astrocytes against hydrogen peroxide-induced apoptosis via a PKA/MAPK-dependent mechanism.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Seyma Bahdoudi; Salma Douiri; Jérôme Leprince; Helene Castel; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

8.  The stimulatory effect of the octadecaneuropeptide ODN on astroglial antioxidant enzyme systems is mediated through a GPCR.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Salma Douiri; Seyma Bahdoudi; Jérôme Leprince; Hélène Castel; Hubert Vaudry; Mohamed Amri; Marie-Christine Tonon; Olfa Masmoudi-Kouki
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-21       Impact factor: 5.555

Review 9.  The diversity of ACBD proteins - From lipid binding to protein modulators and organelle tethers.

Authors:  Markus Islinger; Joseph L Costello; Suzan Kors; Eric Soupene; Timothy P Levine; Frans A Kuypers; Michael Schrader
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-08       Impact factor: 4.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.